The Study of the Crushing Technique Application Using SES in Coronary Bifurcations.

Inclusion Criteria: 1. Is a male or non-pregnant female patient \>= 18 years of age \[NOTE: Females of child-bearing potential must have a negative pregnancy test\]; 2. Has a diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II) OR has documented silent ischemia; 3. Has at least TIMI I coronary flow in both the main and side branches; 4. Involves a single treatment of a de novo bifurcation lesion in native coronary arteries of patients with single or multivessel disease; patients with multiple lesions can be included only if other lesions treated during the index procedure are successfully treated prior to the treatment of the bifurcation lesion; 5. Has a true bifurcation lesion defined as stenosis \> 50% in both the main branch and the ostium of the side branch; 6. Has a maximum treatable main or side branch lesion length \<=28 mm; 7. Has a main branch vessel that is \>= 2.5 mm and \<= 3.5 mm in diameter by on-line QCA proximal to the bifurcation; 8. Has a side branch vessel that is \>= 2.25 mm and \<= 3.5 mm in diameter by on-line QCA; 9. Is an acceptable candidate for coronary artery bypass surgery (CABG); 10. Is willing to comply with the specified follow-up evaluation; 11. The patient or legally authorized representative must provide written informed consent prior to the procedure. Exclusion Criteria: 1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented elevation of CK levels \> 2 times normal or CK-MB levels \> 3 times normal within the preceding 24 hours and/or the CK and CK-MB enzymes remain above normal at the time of treatment; 2. Has unstable angina classified as Braunwald A I-III, B\&C III; 3. Has a bifurcation lesion in a non protected left main; 4. Has an ejection fraction \<= 35%; 5. Has known allergies to the following: aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or sirolimus; 6. Has a known serious allergy to contrast media or stainless steel that cannot be managed medically; 7. Has impaired renal function (creatinine \> 3.0 mg/dl); 8. There is presence of thrombus in the bifurcation lesion; 9. Has a target lesion with excessive tortuousity unsuitable for stent delivery and deployment; 10. Has a totally occluded vessel; 11. Is the recipient of a heart transplant; 12. Has a significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study; 13. Is currently participating in an investigational drug or another device study.